OrbiMed’s Asia angles

With OrbiMed’s largest ever Asia-focused healthcare fund, the firm is not only looking to write larger checks for growth companies, but is also allocating more capital toward innovative Chinese biotechs than in previous funds.

On Sept. 5, OrbiMed announced the final close of OrbiMed Asia Partners III at $551 million, well above the $450 million target. The fund also easily exceeds OrbiMed’s prior two Asia funds: the first closed in 2008 at $182 million and the second in 2014 at $325 million. ...